-
1.发明公开公开(公告)号：US20240325492A1
公开(公告)日：2024-10-03
申请号：US18496799
申请日：2023-10-27
发明人： Afshan MASOOD , Assim ALFADDA , Ibrahim ALRADWAN , Ibrahim ALANAZI , Abdulaziz ALMALIK , Ali ALHASAN , Hicham BENABDELAKMEL , Waleed ALGHAMDI , Haitha ALRABIAH
CPC分类号： A61K38/1741 , A61K9/1652 , A61K9/1676 , A61K47/61 , A61K47/6939
摘要： A protein functionalized anti-inflammatory nanoparticle and a method of preparing the protein functionalized anti-inflammatory nanoparticle is disclosed. The protein functionalized anti-inflammatory nanoparticle includes a central core comprising a hyaluronic acid coated chitosan nanoparticle and surface adsorbed anti-inflammatory proteins forming an outer shell around the central core, wherein the surface adsorbed anti-inflammatory protein is AGP (alpha-1-acid glycoprotein). The method of preparation includes dispersing chitosan nanoparticles in acetic acid/acetate buffer to produce a dispersion, adding an equal amount of acetate buffer containing hyaluronic acid under vigorous stirring to form hyaluronic coated chitosan nanoparticle (HA-CS) and functionalizing the hyaluronic coated chitosan nanoparticle with surface adsorbing anti-inflammatory protein AGP, to form the protein functionalized anti-inflammatory nanoparticle.
-
公开(公告)号：US11779631B2
公开(公告)日：2023-10-10
申请号：US16344985
申请日：2017-11-01
IPC分类号： A61K38/17 , A61K31/395 , A61K38/15 , A61K39/395 , A61P35/00 , C07K16/28 , A61P35/02 , C07K14/705
CPC分类号： A61K38/1741 , A61K31/395 , A61K38/15 , A61K38/1709 , A61K39/395 , A61K39/39541 , A61P35/00 , A61P35/02 , C07K14/70596 , C07K16/2803 , C07K2317/76 , A61K39/39541 , A61K2300/00 , A61K38/15 , A61K2300/00 , A61K38/1709 , A61K2300/00
摘要： CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of depsipeptide and romidepsin as HDAC inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
-
公开(公告)号：US20180179545A1
公开(公告)日：2018-06-28
申请号：US15897290
申请日：2018-02-15
申请人： Kelvin LEE , Abraham Lenhoff , Kristin Valente , Nick Levy , Yatin Gokarn
发明人： Kelvin LEE , Abraham Lenhoff , Kristin Valente , Nick Levy , Yatin Gokarn
IPC分类号： C12N15/113 , C07K16/00 , A61K38/17 , A61K38/39 , A61K38/42 , A61K38/44 , A61K38/45 , A61K38/48 , A61K38/52 , A61K47/26 , C12P21/00 , C12N9/20 , C12P21/02
CPC分类号： C12N15/1137 , A61K38/1709 , A61K38/1741 , A61K38/1761 , A61K38/1774 , A61K38/39 , A61K38/42 , A61K38/44 , A61K38/443 , A61K38/45 , A61K38/4813 , A61K38/482 , A61K38/488 , A61K38/52 , A61K47/26 , C07K16/00 , C12N9/20 , C12N2310/10 , C12N2310/14 , C12N2310/20 , C12P21/005 , C12P21/02 , C12Y104/03013 , C12Y111/01015 , C12Y205/01018 , C12Y207/04006 , C12Y207/11001 , C12Y301/01034 , C12Y304/16005 , C12Y304/21 , C12Y304/23005 , C12Y502/01008 , C12Y503/04001
摘要： The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.
-
4.发明申请公开(公告)号：US20180064786A1
公开(公告)日：2018-03-08
申请号：US15812342
申请日：2017-11-14
申请人： YALE UNIVERSITY
IPC分类号： A61K38/17 , A61K48/00 , C12N15/52 , C12N15/62 , C12N15/85 , C12N9/96 , C07K7/06 , A61K38/04 , C12Q1/68
CPC分类号： A61K38/1741 , A01K67/0271 , A01K2207/15 , A01K2207/20 , A01K2227/105 , A01K2267/0387 , A61K38/02 , A61K38/04 , A61K38/46 , A61K38/465 , A61K48/0058 , A61P9/10 , A61P13/12 , C07K7/06 , C07K14/745 , C07K2319/01 , C07K2319/30 , C07K2319/31 , C07K2319/33 , C07K2319/70 , C12N9/96 , C12N15/52 , C12N15/625 , C12N15/85 , C12N2840/007 , C12Q1/6883 , C12Y301/04001 , C12Y306/01009 , H05K999/99
摘要： The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
-
5.发明申请METHOD FOR TREATING INFECTIOUS DISEASES USING A COMPOSITION COMPRISING PLASMA-DERIVED IMMUNOGLOBULIN M (IgM) 审中-公开使用包含等离子体衍生的免疫球蛋白M（IgM）的组合物治疗感染性疾病的方法公开(公告)号：US20170037115A1
公开(公告)日：2017-02-09
申请号：US15156562
申请日：2016-05-17
发明人： Thomas Barnett , David A. Ross
IPC分类号： C07K16/12 , A61K38/17 , A61K31/407 , A61K39/40 , A61K38/14
CPC分类号： C07K16/1282 , A61K31/407 , A61K38/14 , A61K38/1741 , A61K39/40 , A61K2039/545 , C07K16/12 , C07K16/1214 , C07K16/1232 , C07K16/1271 , C07K2317/52 , C07K2317/76
摘要： Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived IgM and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products.
摘要翻译： 本发明的组合物和方法防止，抑制或降低由微生物分泌的蛋白质和毒素的毒性作用。 用于中和受试者中的微生物蛋白质产物的方法包括向受试者施用组合物，所述组合物包含血浆源IgM和任选的一种或多种药物载体中的赋形剂，其中所述组合物以有效中和微生物蛋白质的量 产品。
-
公开(公告)号：US09132172B2
公开(公告)日：2015-09-15
申请号：US14223909
申请日：2014-03-24
发明人： Robert G Matheny
IPC分类号： A61L27/36 , A61L27/54 , A61K35/38 , A61K35/34 , A61K38/39 , A61K38/18 , A61K45/06 , A61K48/00 , A61K38/20 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , A61K31/505 , A61K9/00
CPC分类号： A61L27/3873 , A61K9/0019 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , A61K31/505 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/18 , A61K38/1825 , A61K38/1841 , A61K38/20 , A61K38/39 , A61K45/06 , A61K48/00 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/40 , A61L27/54 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30 , A61K2300/00
摘要： A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ECM) composition comprising ECM from an adolescent tissue source, the ECM comprising an exogenously added cytokine, and (ii) administering ECM composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule in the ECM composition and modulates ROS production of the cells, whereby, the cellular senescence is abated.
摘要翻译： 一种延缓细胞衰老的方法，包括（i）从青少年组织来源提供包含ECM的细胞外基质（ECM）组合物，所述ECM包含外源加入的细胞因子，和（ii）向具有细胞衰老细胞的器官施用ECM组合物， 其中，细胞因子与ECM组合物中的至少一个分子相互作用并调节细胞的ROS产生，从而减少细胞衰老。
-
7.发明授权公开(公告)号：US09120744B2
公开(公告)日：2015-09-01
申请号：US12624126
申请日：2009-11-23
申请人： Daniel A. Lawrence , Cory Emal , Jacqueline Cale , Enming J. Su , Mark Warnock , Shih-Hon Li , Jeanne A. Cupp
发明人： Daniel A. Lawrence , Cory Emal , Jacqueline Cale , Enming J. Su , Mark Warnock , Shih-Hon Li , Jeanne A. Cupp
IPC分类号： C07C311/29 , C07C69/88 , C07C69/90 , C07C229/12 , C07C229/34 , C07C271/22 , C07C271/54 , C07H13/08
CPC分类号： C07H15/203 , A61K31/166 , A61K31/18 , A61K31/235 , A61K31/27 , A61K31/444 , A61K31/495 , A61K31/50 , A61K31/5375 , A61K31/7034 , A61K38/1741 , A61K38/482 , C07C69/88 , C07C69/90 , C07C69/94 , C07C229/12 , C07C229/34 , C07C235/68 , C07C271/22 , C07C271/54 , C07C311/29 , C07C311/49 , C07C2601/14 , C07D213/82 , C07D295/192 , C07D295/195 , C07D295/26 , C07H13/08 , C12Y304/21073
摘要： The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
-
公开(公告)号：US20150202347A1
公开(公告)日：2015-07-23
申请号：US14193053
申请日：2014-02-28
发明人： Robert G. Matheny
CPC分类号： A61L27/54 , A61K9/0019 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K48/00 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/3873 , A61L27/40 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30
摘要： Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
-
公开(公告)号：US20150157765A1
公开(公告)日：2015-06-11
申请号：US14625684
申请日：2015-02-19
发明人： Robert G. Matheny
CPC分类号： A61L27/54 , A61K9/0019 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K48/00 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/3873 , A61L27/40 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30
摘要： Injectable collagen based graft compositions and grafts formed from the compositions for tissue regeneration. The compositions and grafts further include a glycosaminoglycan (GAG) to control matrix formation and remodeling.
摘要翻译： 可注射的基于胶原的移植组合物和由用于组织再生的组合物形成的移植物。 组合物和移植物还包括用于控制基质形成和重塑的糖胺聚糖（GAG）。
-
公开(公告)号：US09034647B2
公开(公告)日：2015-05-19
申请号：US14269324
申请日：2014-05-05
申请人： Robert G Matheny
发明人： Robert G Matheny
IPC分类号： C12N5/00 , A61F2/00 , A61K35/37 , A61K35/38 , C12N5/02 , A61K38/39 , A61K48/00 , A61L27/36 , A61L27/38 , A61L27/40 , A61K38/17 , A61K38/18 , A61K35/34 , A61K31/726 , A61L27/54 , A61K31/7088 , A61K35/407 , A61K35/22 , A61K9/00
CPC分类号： A61L27/54 , A61K9/0019 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K48/00 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/3873 , A61L27/40 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30
摘要： Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
摘要翻译： 用于再生有缺陷或缺失心肌的本发明的组合物包含乳化或可注射的细胞外基质组合物。 组合物还可以包括任何制剂的细胞外基质支架组分，并且还包括添加的细胞，蛋白质或其它成分以优化再生过程并恢复心脏功能。
-
-
-
-
-
-
-
-
-
搜索结果
134 条记录 (耗时 0.036 秒)
